CompletedNot applicableNCT00346125
PET CT as Predictor of Response in Preoperative Chemotherapy for Soft Tissue Sarcoma
Studying Epithelioid sarcoma
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Masonic Cancer Center, University of Minnesota
- Principal Investigator
- Edward Cheng, MDMasonic Cancer Center, University of Minnesota
- Intervention
- pegfilgrastim(biological)
- Enrollment
- 70 enrolled
- Eligibility
- 16 years · All sexes
- Timeline
- 2006 – 2022
Study locations (2)
- Sinai Hospital of Baltimore, Baltimore, Maryland, United States
- Masonic Cancer Center at University of Minnesota, Minneapolis, Minnesota, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT00346125 on ClinicalTrials.govOther trials for Epithelioid sarcoma
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07089992A Study of Pembrolizumab in People With Ultra-Rare SarcomasMemorial Sloan Kettering Cancer Center
- RECRUITINGPHASE1, PHASE2NCT04390737Evaluate the Safety and Clinical Activity of HH2853Haihe Biopharma Co., Ltd.
- RECRUITINGNCT04300257Swiss Sarcoma Network: Prediction Model for Patient Selection in Sarcoma CareKantonsspital Winterthur KSW
- RECRUITINGNCT03099681An Observational Study on Epithelioid SarcomaItalian Sarcoma Group